Showing results (101-110 of 112) with videos related to
Sort By:
Pageof 12
Journal of Medicinal Chemistry|October 17, 2003
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosisJohn H Hutchinson, Wasyl Halczenko, Karen M Brashear, et al.Journal of Medicinal Chemistry|November 30, 2004
Potent N-(1,3-thiazol-2-yl)pyridin-2-amine vascular endothelial growth factor receptor tyrosine kinase inhibitors with excellent pharmacokinetics and low affinity for the hERG ion channelMark T Bilodeau, Adrienne E Balitza, Timothy J Koester, et al.Bioorganic & Medicinal Chemistry Letters|September 7, 2007
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSPRobert M Garbaccio, Edward S Tasber, Lou Anne Neilson, et al.Journal of Medicinal Chemistry|June 27, 2008
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancerChristopher D Cox, Paul J Coleman, Michael J Breslin, et al.Chemmedchem|February 7, 2012
Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting propertiesPaul J Coleman, John D Schreier, Christopher D Cox, et al.Bioorganic & Medicinal Chemistry Letters|September 25, 2014
Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomniaAnthony J Roecker, Thomas S Reger, M Christa Mattern, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodentsZhi-Qiang Yang, Kelly-Ann S Schlegel, Youheng Shu, et al.The Journal of Biological Chemistry|April 2, 2010
Discovery of the selective androgen receptor modulator MK-0773 using a rational development strategy based on differential transcriptional requirements for androgenic anabolism versus reproductive physiologyAzriel Schmidt, Donald B Kimmel, Chang Bai, et al.Journal of Medicinal Chemistry|June 23, 2010
Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomniaChristopher D Cox, Michael J Breslin, David B Whitman, et al.Journal of Medicinal Chemistry|June 11, 2008
Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonistWilliam D Shipe, James C Barrow, Zhi-Qiang Yang, et al.Pageof 12